巴瑞替尼用于传统合成DMARDs应答不足或不耐受的类风湿关节炎患者:RA-BUILD研究结果
RA-BUILD是一项III期双盲24周研究,纳入684例生物制剂DMARD初治、对至少一种传统合成DMARDs应答不足或不耐受的类风湿关节炎患者,随机接受安慰剂或巴瑞替尼2mg或4mg每日一次。第12周巴瑞替尼4mg组ACR20应答率显著高于安慰剂(62% vs 39%,p≤0.001),且DAS28、SDAI缓解及患者报告结局均显著改善,第24周影像学关节结构损伤进展减轻。
要点
- 巴瑞替尼4mg组第12周ACR20应答率62%,安慰剂组39%,差异有统计学意义(p≤0.001)。
- 巴瑞替尼4mg与安慰剂严重不良事件发生率均为5%,包括严重感染在内总体相似。
- 巴瑞替尼4mg组报告1例结核和1例非黑色素瘤皮肤癌不良事件。
核心结论
- 在对传统合成DMARDs应答不足或不耐受的类风湿关节炎患者中,巴瑞替尼与临床改善及影像学关节损伤进展抑制相关。
研究设计与样本
- III期双盲24周研究,纳入684例生物制剂DMARD初治且对至少一种传统合成DMARDs应答不足或不耐受的类风湿关节炎患者,按1:1:1随机分配至安慰剂或巴瑞替尼2mg或4mg每日一次,按地区和关节侵蚀存在与否分层。
主要发现
- 第12周巴瑞替尼4mg组ACR20应答率62%,安慰剂组39%,p≤0.001。
- 与安慰剂相比,巴瑞替尼组DAS28、SDAI缓解、HAQ-DI、晨僵、最严重关节疼痛和最严重疲劳均观察到统计学显著改善。
- 支持性分析显示第24周巴瑞替尼组影像学关节结构损伤进展较安慰剂减轻。
- 治疗期间不良事件和严重不良事件(包括严重感染)发生率组间相似,巴瑞替尼4mg组和安慰剂组严重不良事件均为5%。
- 巴瑞替尼4mg组报告1例结核不良事件和1例非黑色素瘤皮肤癌不良事件;安慰剂组发生2例死亡和3例主要不良心血管事件。
关键数值与推荐
- 主要终点为第12周ACR20应答率。
- 其他终点包括DAS28、SDAI评分≤3.3、HAQ-DI、晨僵、最严重关节疼痛和最严重疲劳。
临床怎么用
- 对于传统合成DMARDs应答不足或不耐受且生物制剂DMARD初治的类风湿关节炎患者,巴瑞替尼4mg每日一次可考虑作为治疗选择。
- 使用巴瑞替尼期间需关注中性粒细胞下降及血脂变化,并警惕结核和皮肤癌等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS: In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3.3. RESULTS: More patients achieved ACR20 response at week 12 with baricitinib 4 mg than with placebo (62% vs 39%, p≤0.001). Compared with placebo, statistically significant improvements in DAS28, SDAI remission, Health Assessment Questionnaire-Disability Index, morning joint stiffness, worst joint pain and worst tiredness were observed. In a supportive analysis, radiographic progression of structural joint damage at week 24 was reduced with baricitinib versus placebo. Rates of adverse events during the treatment period and serious adverse events (SAEs), including serious infections, were similar among groups (SAEs: 5% for baricitinib 4 mg and placebo). One patient had an adverse event of tuberculosis (baricitinib 4 mg); one patient had an adverse event of non-melanoma skin cancer (baricitinib 4 mg). Two deaths and three major adverse cardiovascular events occurred (placebo). Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein. CONCLUSIONS: In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage. TRIAL REGISTRATION NUMBER: NCT01721057; Results.
引用
- Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2016. PMID: 27689735. doi:10.1136/annrheumdis-2016-210094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。